ClinicalTrials.gg

Program

Gallium Ga 68 NNS309

In Novartis’s pipeline, Radioligand therapy target FAP. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Novartis.

Furthest: phase 1, since Nov 21, 20252 company-led studies, 2 open or runningNext primary completion: Jan 16, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis22 open or runningphase 1since Nov 21, 2025Nov 21, 2025Jan 16, 2028phase 1 · NCT07630961

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07261631 · 180 planned · United States, Canada, Denmark and more
  2. Jun 1, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07630961 · 66 planned · Denmark, Japan

Ahead

  1. Jan 16, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07630961
  2. May 9, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07261631

TargetBeta

“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FAPI-74rulesofiephase 33
Fluorine F 18 FPyQCPruleBraccophase 21
HRS-6768Jiangsu HengRui Medicinephase 21
Anti-FAP Antibody-drug Conjugate OMTX705ruleoncomatryx-biopharma-s-lphase 12
Actinium Ac 225 RTX-2358ruleratio-therapeutics-incphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07630961Carcinoma, Non-Small-Cell Lung · Denmark, Japan1RecruitingJan 16, 202866
NCT07261631Carcinoma, Non-Small-Cell Lung · United States, Canada, Denmark and more1RecruitingMay 9, 2029180

How it is read

Names in the registry

  • “68Ga-NNS309”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.